Piper Sandler Maintains Overweight on Nektar Therapeutics, Raises Price Target to $192
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Yasmeen Rahimi maintains Nektar Therapeutics (NASDAQ:NKTR) with a Overweight and raises the price target from $105 to $192.
Piper Sandler analyst Yasmeen Rahimi maintains Nektar Therapeutics (NASDAQ:NKTR) with a Overweight and raises the price target from $105 to $192.